Videos and Podcasts
Gary Phillips, CEO of Australian biopharma company, Pharmaxis Ltd, discusses ensuring continuity of supply of its products throughout the crisis, the timeframe for trials of its unique anti-fibrotic treatment for a rare bone cancer, broader impacts for biopharma research and trials, the opportunity for the global industry and the potential for PXS respiratory products in the clinical aftermath of COVID -19.
Recorded 29 April 2020.
Listen to the podcast here.
Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips presented at the NWR Virtual Health Conference on Friday 1 May 2020.
Investors may view a recording of the presentation at the NWR website: https://us02web.zoom.us/webinar/register/WN_pdWZYlHJRFmjH01LYGc0NQ
Gary Phillips tells Proactive's Andrew Scott they're progressing to a phase II study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF). The move comes on the back of positive results from its phase 1b trial and long-term toxicity studies.